StockNews.com assumed coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note issued to investors on Thursday. The brokerage issued a sell rating on the stock. Navidea Biopharmaceuticals Stock Performance Shares of NAVB opened at $0.00 on Thursday. Navidea Biopharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week […]